醫藥品批發·流通產業:全球展望(2011∼2021年)

醫藥品批發·流通產業:全球展望(2011∼2021年) 是由出版商Visiongain在2011年04月所出版的。 這份英文市場調查報告書包含180 Pages 價格從美金2331起跳。

簡介

本報告提供2011年∼2021年的醫藥品的批發·流通產業趨勢相關調查分析，醫藥品流通連鎖的主要趨勢和機會，收益預測，產業的SWOT分析等資料，為您概述為以下內容。

第1章 摘要整理

第2章 產業及市場的簡介

• 醫藥品批發商所扮演的角色
  • 全通路批發商
  • 部分通路批發商
• 流通連鎖
  • 二級批發商
  • 藥局直接銷售
  • 藥局利益管理者
• 創造收入
  • 遠期採購
  • 服務費
  • 折扣
  • 回本及批發業者
  • 回扣
  • 平行貿易

第3章 全球醫藥品批發·流通市場:2011∼2021年

• 全球市場:2009年
• 全球市場預測:2011∼2021年
• 美國
• 歐洲
  • 德國
  • 法國
  • 西班牙
  • 英國
  • 義大利
• 日本
• 中國
• 巴西
• 俄羅斯
• 不同地區市場佔有率:2011∼2021年

第4章 全球主要的批發業者:2011∼2021年

• 收益和利益
• 主要企業
  • McKesson
  • AmerisourceBergen
  • The Phoenix Group
  • Celesio
  • Alfresa Holdings
  • Medipal
  • Alliance Boots
  • Suzuken

第5章 市場定性分析:2011∼2021年

• SWOT分析
• 優勢
• 弱點
• 機會
• 威脅

第6章 醫藥品批發產業趨勢:2011∼2021年

• 假藥對策
• 特殊醫藥品的增加
• 產業整合
• 連鎖藥局和垂直整合

第7章 研究的意見

第8章 結論

圖表

目錄

Abstract

how will events this decade affect those activities?

How will the pharma wholesale and distribution industry perform from 2011 onwards? Our new report shows you that industry and market' s revenue potential from 2011 to 2021.

There, you will assess the trends and opportunities shaping the pharmaceutical distribution chain. We aim to save you time and aid your decisions through our research, analysis and discussions.

Our report shows you revenue prospects for pharmaceutical wholesale and distribution activities at total world, company and national levels.

We forecast revenues of McKesson (US), Cardinal Health (US), AmerisourceBergen (US), The Phoenix Group (Europe), Celesio (Europe), Alfresa Holdings (Japan), Medipal (Japan), Alliance Boots (Europe) and Suzuken (Japan). You will discover their prospects to 2021.

What effects will healthcare budget cuts have on pharmaceutical wholesalers? Which national markets will provide the best opportunities from 2011 to 2021? How common will direct-to-pharmacy distribution become? Our work provides answers you need.

We help you to assess the pharma wholesale and distribution industry' s strengths, weaknesses, trends and revenue opportunities to 2021. You will see where the industry and market are heading.

Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.

Industry and market analysis to help your work - so you won' t be left behind

Our report gives you revenue forecasts, growth rates and market shares. We also provide a SWOT/STEP review, analysis of companies and external opinions from our industry survey.

We include 117 tables and charts and two research interviews (shown in the accompanying lists). Our study helps you to understand pharma wholesaling and distribution this decade.

Pharmaceutical Wholesale and Distribution Industry: World Outlook 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:

• You will receive hard data for the pharmaceutical wholesale and distribution industry and market from 2009 to 2021
• You will discover revenue forecasting for the overall world market from 2011 to 2021
• You will assess leading companies in the pharma distribution chain, discovering their activities, potential revenue values and commercial outlooks to 2021
• You will find revenue predictions for leading geographical markets to 2021 (US, Japan, China, Germany, France, UK, Spain, Italy, Brazil and Russia)
• You will investigate competition and opportunities that will influence revenues
• You will see what will stimulate and restrain the industry and market
• You will view opinion from our survey, including full interview transcripts.

That mix of quantitative and qualitative market analysis sets our report apart. Our independent analysis helps you to stay ahead in commercial knowledge.

Order our report now to gain industry and market information you need

Our report can benefit everybody interested in pharmaceutical wholesaling and distribution. We give predictions and answers you need. Don' t miss out - please order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Executive Summary

• 1.1. Overview of the Study
• 1.2. Chapter Breakdown
• 1.3. Research and Analysis Methods

2. Introduction to the Industry and Market

• 2.1. The Role of Pharmaceutical Wholesalers
  • 2.1.1. Full-Line Wholesalers (FLWs)
  • 2.1.2. Short-Line Wholesalers (SLWs)
• 2.2. The Chain of Distribution
  • 2.2.1. Secondary Wholesalers
  • 2.2.2. Direct-to-Pharmacy
  • 2.2.3. Pharmacy Benefit Managers
• 2.3. Generating Revenue and Profit
  • 2.3.1. Forward Buying
  • 2.3.2. Fee-for-Service
    • 2.3.2.1. Inventory Management Agreements
  • 2.3.3. Discounts
  • 2.3.4. Reimbursement and Wholesalers
  • 2.3.5. Clawback
  • 2.3.6. Parallel Trade

3. The World Pharmaceutical Wholesale and Distribution Market 2011-2021

• 3.1. The World Market in 2009
• 3.2. World Market Forecast 2011-2021
• 3.3. The US
  • 3.3.1. An Increase in Fee-for-Service Activity
  • 3.3.2. US Market Forecast 2011-2021
• 3.4. Europe
  • 3.4.1. Differences between the US and Europe
    • 3.4.1.1. State-Funded Healthcare and Reimbursement
  • 3.4.2. European Market Forecast 2011-2021
  • 3.4.3. Germany
    • 3.4.3.1. Healthcare Reform
    • 3.4.3.2. Market Forecast 2011-2021
  • 3.4.4. France
    • 3.4.4.1. Market Forecast 2011-2021
  • 3.4.5. Spain
    • 3.4.5.1. Market Forecast 2011-2021
  • 3.4.6. The UK
    • 3.4.6.1. Price Cuts 2009-2010
    • 3.4.6.2. Market Forecast 2011-2021
  • 3.4.7. Italy
    • 3.4.7.1. Market Forecast 2011-2021
• 3.5. Japan
  • 3.5.1. Drug Pricing and Performance Fees
  • 3.5.2. Market Forecast 2011-2021
• 3.6. China
  • 3.6.1. Leading Companies 2009-2010
  • 3.6.2. Recent Market Developments
  • 3.6.3. Market Forecast 2011-2021
• 3.7. Brazil
  • 3.7.1. Leading Companies 2009-2010
  • 3.7.2. Market Forecast 2011-2021
• 3.8. Russia
  • 3.8.1. Market Trends
  • 3.8.2. Market Forecast 2011-2021
• 3.9. Regional Market Shares 2011-2021

4. Leading Wholesalers in the Global Market 2011-2021

• 4.1. Revenue vs. Profit
  • 4.1.1. Profit Margins 2009
• 4.2. Leading Companies Market Forecast 2011-2021
• 4.3. McKesson
  • 4.3.1. Recent Performance
  • 4.3.2. Future Strategies
  • 4.3.3. Revenue Forecast 2011-2021
• 4.4. Cardinal Health
  • 4.4.1. Segment Reorganisation
  • 4.4.2. Recent Performance
  • 4.4.3. Future Strategies
  • 4.4.4. Revenue Forecast 2011-2021
• 4.5. AmerisourceBergen
  • 4.5.1. Recent Performance
  • 4.5.2. Future Strategies
  • 4.5.3. Revenue Forecast 2011-2021
• 4.6. The Phoenix Group
  • 4.6.1. Recent Performance
  • 4.6.2. The Tamro Group 2009-2010
  • 4.6.3. Future Strategies
  • 4.6.4. Revenue Forecast 2011-2021
• 4.7. Celesio
  • 4.7.1. Recent Performance
  • 4.7.2. Future Strategies
  • 4.7.3. Revenue Forecast 2011-2021
• 4.8. Alfresa Holdings
  • 4.8.1. Recent Performance
  • 4.8.2. Future Strategies
  • 4.8.3. Revenue Forecast 2011-2021
• 4.9. Medipal
  • 4.9.1. Recent Performance
  • 4.9.2. Future Strategies
  • 4.9.3. Revenue Forecast 2011-2021
• 4.10. Alliance Boots
  • 4.10.1. Recent Performance
  • 4.10.2. Future Strategies
  • 4.10.3. Revenue Forecast 2011-2021
• 4.11. Suzuken
  • 4.11.1. Recent Performance
  • 4.11.2. Future Strategies
  • 4.11.3. Revenue Forecast 2011-2021

5. Qualitative Analysis of the Market 2011-2021

• 5.1. SWOT Chart for the Pharmaceutical Wholesale and Distribution Market 2011-2021
• 5.2. Strengths
  • 5.2.1. Large Companies Dominate the Market
  • 5.2.2. Wholesalers Do More than Deliver Drugs
    • 5.2.2.1. Pre-Wholesaling
• 5.3. Weaknesses
  • 5.3.1. Counterfeiting
  • 5.3.2. Low Margins
• 5.4. Opportunities
  • 5.4.1. Increased Demand for Pharmaceuticals
  • 5.4.2. Generics
  • 5.4.3. Globalisation
• 5.5. Threats
  • 5.5.1. Direct-to-Pharmacy (DTP)
    • 5.5.1.1. DTP in Europe
    • 5.5.1.2. The UK
    • 5.5.1.3. Poland
    • 5.5.1.4. DTP in Australia
    • 5.5.1.5. Further Expansion
  • 5.5.2. Healthcare Budget Cuts
  • 5.5.3. Diversion and Re-importation
  • 5.5.4. Supermarket Pharmacies
    • 5.5.4.1. Case Study: Walmart

6. Pharmaceutical Wholesale Industry Trends 2011-2021

• 6.1. Combating Counterfeit Medicines
  • 6.1.1. The US and E-Pedigree
  • 6.1.2. European Pedigree Legislation
  • 6.1.3. Anti-Counterfeiting Strategies in Other Markets
  • 6.1.4. Issues in Serialisation for Wholesalers
• 6.2. Growth in Specialty Pharmaceuticals
• 6.3. Industry Consolidation
• 6.4. Chain Pharmacies and Vertical Integration

7. Opinions from Our Survey

• 7.1. Professor David Taylor, Professor of Pharmaceutical and Public Health Policy, University of London
  • 7.1.1. The Purpose of DTP
  • 7.1.2. The Impact of DTP on Pharmacies
  • 7.1.3. Changes to Drug Pricing in the UK
  • 7.1.4. DTP and the Patient
  • 7.1.5. Wholesale Trends Across Europe
• 7.2. Dr Heinz Kobelt, Secretary-General, European Association of Euro-Pharmaceutical Companies (EAEPC)
  • 7.2.1. Benefits of Parallel Trade
  • 7.2.2. Generics and Parallel Trade
  • 7.2.3. Parallel Traders Combating Counterfeiting
  • 7.2.4. The DTP Model

8. Conclusions

• 8.1. There Will Be Steady Growth in Developed Markets
  • 8.1.1. Generics Will Threaten Revenues
  • 8.1.2. Manufacturers Will Deliver Direct More Regularly
  • 8.1.3. There Will Be Greater Demand for Specialty Medicines
• 8.2. Growth Will Be Faster in Emerging Markets
  • 8.2.1. Consolidation Will Drive Growth
• 8.3 .Anti-Counterfeiting Demands Will Add to Wholesalers' Costs

List of Tables

• Table 2.1: Prevalence of the DTP Model in the UK, 2011
• Table 3.1: Global Pharmaceutical Wholesale and Distribution Market by Country, 2009
• Table 3.2: Global Pharmaceutical Wholesale Market Forecast, 2009-2021
• Table 3.3: Global Market Drivers and Restraints, 2011-2021
• Table 3.4: US Pharmaceutical Wholesale and Distribution Market by Company, 2009
• Table 3.5: US Market Drivers and Restraints, 2011-2021
• Table 3.6: European Pharmaceutical Wholesale and Distribution Market by Country, 2009
• Table 3.7: How Price Controls Vary Across Europe, 2010
• Table 3.8: European Market Drivers and Restraints, 2011-2021
• Table 3.9: European Pharmaceutical Wholesale Market Forecast, 2009-2021
• Table 3.10: German Market Drivers and Restraints, 2011-2021
• Table 3.11: French Market Drivers and Restraints, 2011-2021
• Table 3.12: Spanish Market Drivers and Restraints, 2011-2021
• Table 3.13: UK Pharmaceutical Wholesale and Distribution Market by Company, 2009
• Table 3.14: UK Market Drivers and Restraints, 2011-2021
• Table 3.15: Italian Market Drivers and Restraints, 2011-2021
• Table 3.16: Japanese Points of Delivery, 2011
• Table 3.17: Japanese Pharmaceutical Wholesale and Distribution Market, 2009
• Table 3.18: Global Population Aged Over 65, 2009-2025
• Table 3.19: Japanese Market Drivers and Restraints, 2011-2021
• Table 3.20: Chinese Market Drivers and Restraints, 2011-2021
• Table 3.21: Brazilian Market Drivers and Restraints, 2011-2021
• Table 3.22: Russian Pharmaceutical Wholesale and Distribution Market, 2009
• Table 3.23: Russian Market Drivers and Restraints, 2011-2021
• Table 4.1: Leading Companies in the Market, 2009
• Table 4.2: Company Year End Revenues, 2009
• Table 4.3: Profit Margins Reported by Leading Companies, 2009
• Table 4.4: Market Leaders: Drivers and Restraints, 2011-2021
• Table 4.5: Pharmaceutical Wholesale Market Leaders: Forecast, 2009-2021
• Table 4.6: McKesson Pharmaceutical Wholesale Revenue by Country, 2009
• Table 4.7: McKesson Pharmaceutical Wholesale Revenue and Gross Profit by Quarter, 2009
• Table 4.8v McKesson Wholesale Revenue Forecast, 2009-2021
• Table 4.9: Cardinal Health' s Bulk and Non-bulk Orders, 2009-2010
• Table 4.10: Cardinal Health Wholesale Revenue Forecast, 2009-2021
• Table 4.11: AmerisourceBergen Pharmaceutical Distribution Revenue and Gross Profit by Quarter, 2009
• Table 4.12: AmerisourceBergen Pharmaceutical Distribution Revenue and Gross Profit, Q1-Q3 2010
• Table 4.13: AmerisourceBergen Wholesale Revenue Forecast, 2009-2021
• Table 4.14: The Phoenix Group Wholesale Subsidiaries, 2010
• Table 4.15: The Phoenix Group Revenue and Gross Profit, February-October 2009-2010
• Table 4.16: Tamro Group Revenue, 2009-2010
• Table 4.17: The Phoenix Group Wholesale Revenue Forecast, 2009-2021
• Table 4.18: Celesio Wholesale Subsidiaries, 2010
• Table 4.19: Celesio Wholesale Revenue by Country, 2009
• Table 4.20: Celesio Wholesale Revenue Forecast, 2009-2021
• Table 4.21: Alfresa Wholesale Subsidiaries, 2010
• Table 4.22: Alfresa Wholesale Revenue and Operating Income by Quarter, 2009
• Table 4.23: Alfresa Wholesale Revenue Forecast, 2009-2021
• Table 4.24: Medipal Wholesale Revenue and Operating Income by Quarter, 2009
• Table 4.25: Medipal Wholesale Revenue and Operating Income, Q1-Q3 2010
• Table 4.26: Medipal Wholesale Revenue Forecast, 2009-2021
• Table 4.27: Alliance Boots Wholesale Revenue by Country, 2009
• Table 4.28: Alliance Boots Wholesale Revenue Forecast, 2009-2021
• Table 4.29: Suzuken Wholesale Revenue and Operating Income by Quarter, 2009
• Table 4.30: Suzuken Wholesale Revenue and Operating Income, Q1-Q3 2010
• Table 4.31: Suzuken Wholesale Revenue Forecast, 2009-2021
• Table 5.1: SWOT Chart for the Pharmaceutical Wholesale and Distribution Market, 2011-2021
• Table 5.2: Revenues for Leading Wholesalers and Manufacturers, 2009
• Table 5.3: Regional Split of Counterfeiting Incidents, 2009
• Table 5.4: Global Recorded Incidents of Counterfeit Medicines, 2002-2009
• Table 5.5: Strengths and Weaknesses of the DTP Model
• Table 8.1: Global Pharmaceutical Wholesale Market Shares by Country, 2009, 2015 and 2021
• Table 8.2: US Patent Expiries for Leading Small Molecule Drugs, 2010-2012

List of Figures

• Figure 2.1: Traditional Routes of Drug Distribution, 2011
• Figure 2.2: CVS Caremark Revenue by Segment, 2009
• Figure 3.1: Global Pharmaceutical Wholesale and Distribution Market by Country, 2009
• Figure 3.2: Global Pharmaceutical Wholesale Market Forecast, 2009-2021
• Figure 3.3: US Pharmaceutical Wholesale and Distribution Market by Company, 2009
• Figure 3.4: US Pharmaceutical Wholesale Market Forecast, 2009-2021
• Figure 3.5: European Pharmaceutical Wholesale and Distribution Market by Country, 2009
• Figure 3.6: European Pharmaceutical Wholesale Market Forecast, 2009-2021
• Figure 3.7: German Pharmaceutical Wholesale Market Forecast, 2009-2021
• Figure 3.8: French Pharmaceutical Wholesale Market Forecast, 2009-2021
• Figure 3.9: Spanish Pharmaceutical Wholesale Market Forecast, 2009-2021
• Figure 3.10: UK Pharmaceutical Wholesale and Distribution Market by Company, 2009
• Figure 3.11: UK Pharmaceutical Wholesale Market Forecast, 2009-2021
• Figure 3.12: Italian Pharmaceutical Wholesale Market Forecast, 2009-2021
• Figure 3.13: Japanese Points of Delivery, 2011
• Figure 3.14: Japanese Pharmaceutical Wholesale and Distribution Market, 2009
• Figure 3.15: Changes to Japanese Drug Pricing, 2010
• Figure 3.16: Aging Global Population, 2009-2025
• Figure 3.17: Japanese Pharmaceutical Wholesale Market Forecast, 2009-2021
• Figure 3.18: Chinese Pharmaceutical Wholesale Market Forecast, 2009-2021
• Figure 3.19: Brazilian Pharmaceutical Wholesale Market Forecast, 2009-2021
• Figure 3.20: Russian Pharmaceutical Wholesale and Distribution Market, 2009
• Figure 3.21: Russian Pharmaceutical Wholesale Market Forecast, 2009-2021
• Figure 3.22: Global Pharmaceutical Wholesale and Distribution Market by Country, 2015
• Figure 3.23: Global Pharmaceutical Wholesale and Distribution Market by Country, 2021
• Figure 4.1: Leading Companies in the Market, 2009
• Figure 4.2: Pharmaceutical Wholesale Market Leaders: Forecast, 2009-2021
• Figure 4.3: McKesson Pharmaceutical Wholesale Revenue by Country, 2009
• Figure 4.4: McKesson Pharmaceutical Wholesale Revenue and Gross Profit by Quarter, 2009
• Figure 4.5: McKesson Wholesale Revenue Forecast, 2009-2021
• Figure 4.6: Cardinal Health Pharmaceutical Revenue by Company, FY 2009-2010
• Figure 4.7: Cardinal Health' s Bulk and Non-bulk Orders, FY 2009-2010
• Figure 4.8: Cardinal Health Wholesale Revenue Forecast, 2009-2021
• Figure 4.9: AmerisourceBergen Pharmaceutical Distribution Revenue by Quarter, 2009
• Figure 4.10: AmerisourceBergen Wholesale Revenue Forecast, 2009-2021
• Figure 4.11: The Phoenix Group Wholesale Revenue, February-October 2009-2010
• Figure 4.12: Tamro Group Revenue, 2009-2010
• Figure 4.13: The Phoenix Group Wholesale Revenue Forecast, 2009-2021
• Figure 4.14: Celesio Wholesale Revenue by Country, 2009
• Figure 4.15: Celesio Wholesale Revenue Forecast, 2009-2021
• Figure 4.16: Alfresa Wholesale Operating Income Margin by Quarter, 2009
• Figure 4.17: Alfresa Wholesale Revenue Forecast, 2009-2021
• Figure 4.18: Medipal Wholesale Revenue by Quarter, 2009
• Figure 4.19: Medipal Wholesale Operating Income Margin, Q1-Q3 2009-2010
• Figure 4.20: Medipal Wholesale Revenue Forecast, 2009-2021
• Figure 4.21: Alliance Boots Wholesale Revenue by Country, 2009
• Figure 4.22: Alliance Boots Wholesale Revenue Forecast, 2009-2021
• Figure 4.23: Suzuken Wholesale Revenue by Quarter, 2009
• Figure 4.24: Suzuken Wholesale Operating Income Margin, Q1-Q3 2010
• Figure 4.25: Suzuken Wholesale Revenue Forecast, 2009-2021
• Figure 5.1: Revenues for Leading Wholesalers and Manufacturers, 2009
• Figure 5.2: Regional Split of Counterfeiting Incidents, 2009
• Figure 5.3: Global Recorded Incidents of Counterfeit Medicines, 2002-2009
• Figure 5.4: Comparison of the Wholesaler and Direct-to-Pharmacy Routes
• Figure 6.1: Anti-Counterfeiting Strategies in the US and Europe, 2011

Companies Listed

• Acofarma (Asociacion Cooperativas Farmaceuticas) [Spain]
• Alfresa Holdings and its subsidiaries:
• Alfresa
• Alfresa Medical Service
• Alfresa Nikken Sangyo
• Ando Co
• CS Yakuhin Co
• Kowa Pharmaceuticals Co
• Meisho Co
• Odashima
• Ryuyaku Co
• Seiwa Sangyo Co
• Shikoku Alfresa
• Alliance Boots and its subsidiaries:
• Alliance Healthcare
• Alloga
• Almus Pharmaceuticals
• Andreae-Noris Zahn (ANZAG) [Germany]
• Cordia Healthcare
• Galenica
• Hedef Alliance Holding
• HydraPharm [Algeria]
• Megapharm [Germany]
• UCP [Egypt]
• AmerisourceBergen and its subsidiaries:
• American Health Packaging
• Anderson Packaging
• Brecon Pharmaceuticals
• Astellas Pharma
• AstraZeneca
• Athos Farma
• Australian Pharmaceutical Industries
• Barr Pharmaceuticals (now part of Teva Pharmaceuticals)
• Bayer
• Bristol-Myers Squibb
• British Association of Pharmaceutical Wholesalers (BAPW)
• Bundesverband des Pharmazeutischen Grosshandel (PHAGRO) [Germany]
• Cardinal Health and its subsidiaries:
• Kinray
• MediCap Pharmacy
• Medicine Shoppe International
• Zuellig Pharma China (Yong Yu)
• CareFusion
• Celesio and its subsidiaries:
• AAH Pharmaceuticals [UK]
• Admenta Italia [Italy]
• Cahill May Roberts [Ireland]
• Evolution Homecare [UK]
• GEHE [Germany]
• GEHE Pharma Praha [Czech Republic]
• Herba Chemosan [Austria]
• Inten [Germany]
• Kemofarmacija [Slovenia]
• Laboratoria Flandria [Belgium]
• Norsk Medisinaldepot [Norway]
• OCP [France/Portugal]
• Panpharma [Brazil]
• Pharma Belgium [Belgium]
• Pharmactiv [France]
• Tjellesen Max Jenne [Denmark]
• Vitapharm [Slovenia]
• Center for Medicine in the Public Interest [US]
• CERP France (CERP Bretagne Nord, CERP Rhin Rhone Mediterranee and CERP Rouen)
• Chambre Syndicale de la Repartition Pharmaceutique (CSRP) [France]
• China Health Systems
• China National Pharmaceutical Group (Sinopharm)
• Cofares Hefame (formerly Cofares and Hefame)
• CVS Caremark (formerly CVS and Caremark Rx)
• Department of Health [UK]
• Eli Lilly
• European Association of Euro-Pharmaceutical Companies (EAEPC)
• European Federation of Pharmaceutical Industries and Associations (EFPIA)
• GlaxoSmithKline (GSK)
• Guangzhou Pharmaceuticals
• Healthcare Distribution Management Association (HDMA) [US]
• Hubei Kyoso Pharmaceutical (a Toho and Jointown joint venture)
• Humana
• Johnson & Johnson (J&J)
• Japanese Pharmaceutical Wholesalers Association (JPWA)
• Jointown Pharmaceutical Group
• Katren
• KL Holding
• Kohlberg Kravis Roberts & Co (KKR)
• McKesson and its subsidiaries:
• Nadro
• Oncology Therapeutics Network
• Parata Systems
• US Oncology
• Medco Health Solutions
• Medipal and its subsidiaries:
• Atol Co
• Chiyaku Co
• Everlth Co
• Izutsu Pharmaceutical Co
• Kobashou Co
• Kuraya Sanseido (now Mediceo)
• Heisei Yakuhin Co
• Nakagawa Seikodo Co
• Sinopharm Medicine Holding Beijing Huahong
• Ushioda Sagokudo Yakuhin Co
• Ministry of Commerce [China]
• Mitsubishi
• Napp Pharmaceutical Group
• National Association of Boards of Pharmacy (NABP) [US]
• National Health Service (NHS) [UK]
• Novartis
• Novo Nordisk
• Pfizer
• Pharmaceutical Security Institute (PSI) [US]
• Polish Pharmaceutical Chamber
• Polska Grupa Farmaceutyczna
• Profarma
• Prosper
• Protek
• ratiopharm
• Rite-Aid
• Roche
• Rosta Pharmaceutical Group
• Sanacorp
• sanofi-aventis
• Shanghai Pharmaceutical Group
• SIA International
• Sigma Pharmaceuticals
• Sincamesp [Brazil]
• State Food and Drug Administration (SFDA) [China]
• Suzuken and its subsidiaries:
• Astis Co
• Jingu Yakuhin Co
• Nakano Yakuhin Co
• Sanki
• Shanghai Suzuken Huzhong Pharmaceutical
• Shoyaku Co
• Suzuken Iwate Co
• Suzuken Okinawa Yakuhin Co
• Target
• Teva Pharmaceuticals
• The Phoenix Group and its subsidiaries:
• Amedis-UE [Switzerland]
• Apokjeden Group [Norway]
• Brocacef Holding [The Netherlands]
• Gruppo Comifar [Italy]
• Libra [Bulgaria]
• Nomeco [Denmark]
• Numark [UK]
• Phoenix Arzeiwarengro?handlung [Austria]
• Phoenix Farmacija [Croatia]
• Phoenix Lekarensky [Czech Republic]
• Phoenix Healthcare Distribution [UK]
• Phoenix Pharma [France/Hungary/Serbia]
• Phoenix Pharma Polska [Poland]
• Phoenix Pharmahandel [Germany]
• Phoenix Zdravotnicke zasobovanie [Slovakia]
• Rowlands [UK]
• Tamro [Sweden]
• SIA Tamro [Latvia]
• Tamro Suomi [Finland]
• Tamro Eesti [Estonia]
• UAB Tamro [Lithuania]
• Toho Holdings
• Torfarm
• United Nations (UN)
• Walgreens
• Walmart
• Wyeth Pharmaceuticals (now part of Pfizer)

相關商品

OTC 非處方藥相關市場調查報告書

處方藥改列成藥策略:體重管理與戒煙的新轉換機會，仍存有自我保健的引進促進的課題
Rx-to-OTC Switching Strategies - New Switching Opportunities in Weight Management and Smoking Cessation, but Encouraging the Uptake of Self-Medication Remains a Challenge
價格 : US $ 3500
出版日期 : 2012年04月

全球消費者保健品市場上新產品開發
New Product Developments in Consumer Health
價格 : US $ 2000
出版日期 : 2012年04月

地區概要:亞太地區的消費者保健品趨勢
Regional Overview: Consumer Health Trends in Asia Pacific
價格 : US $ 2000
出版日期 : 2012年03月

Visiongain發行的製藥相關市場調查報告書

醫藥品主要企業系列:前50大學名藥廠商企業 2012-2022年

Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022

價格 : US $ 2642

出版日期 : 2012年03月

眼科用醫藥品的全球市場預測

Ophthalmic Drugs: World Market Prospects 2012-2022

價格 : US $ 2642

出版日期 : 2012年03月

主要抗癌藥及相關市場:2012-2022年

Leading Anti-Cancer Drugs and Associated Market 2012-2022

價格 : US $ 2642

出版日期 : 2012年02月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!